Patents by Inventor Jörg Kreuter

Jörg Kreuter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120263739
    Abstract: The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 18, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Klaus Langer, Marion Anhorn, Joerg Kreuter, Florian Rothweiler, Hagen von Briesen, Sylvia Wagner, Martin Michaelis, Jindrich Cinatl
  • Publication number: 20110293730
    Abstract: A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles.
    Type: Application
    Filed: July 20, 2011
    Publication date: December 1, 2011
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Jörg Kreuter, Svetlana Gelperina, Olga Maksimenko, Alexander Khalanskiy
  • Patent number: 8003128
    Abstract: A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: August 23, 2011
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Jörg Kreuter, Svetlana Gelperina, Olga Maksimenko, Alexander Khalanskiy
  • Patent number: 7985427
    Abstract: The invention relates to a gastric juice-resistant device for releasing active substance excipients having delayed intestinal passage from a gastric juice-resistant enclosure, and which serves to increase the active substance concentration in the intestines. The inventive device is characterized in that the active substance excipient containing at least one active substance is provided in the form of a multiparticulate preparation whose individual particles have mucoadhesive properties. The invention also relates to a method for producing said device.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: July 26, 2011
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Despina Solomonidou, Markus Krumme, Bodo Asmussen, Joerg Kreuter
  • Publication number: 20100028446
    Abstract: Combination preparations comprising at least one apolipoprotein as one component, and a medicinal agent to be transported via the blood-brain barrier to the central nervous system as a further component. The components are administered simultaneously, separately or sequentially. A method for administering a medicinal agent to the central nervous system is also provided.
    Type: Application
    Filed: February 1, 2008
    Publication date: February 4, 2010
    Inventors: Jörg Kreuter, Klaus Langer, Sebastian Dreis, Telli Hekmatara
  • Publication number: 20090304720
    Abstract: Active agent-loaded nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins, and methods for producing the nanoparticles and the use thereof. Functional proteins or peptide fragments are bound to the nanoparticles via polyethylene glycol-?-maleimide-?-NHS esters.
    Type: Application
    Filed: February 27, 2007
    Publication date: December 10, 2009
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Jörg Kreuter, Klaus Langer, Kerstin Michaelis, Telli Hekmatara, Sebastian Dreis
  • Publication number: 20090181090
    Abstract: Nanoparticles, the particle matrix of which is based on at least one protein and has at least one active agent embedded therein and methods of producing the nanoparticles with at least one active agent embedded in the protein matrix are disclosed. The use of the nanoparticles for the treatment of tumours, in particular for the treatment of tumours which are resistant to chemical medicaments is also disclosed.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 16, 2009
    Inventors: Sebastian Dreis, Klaus Langer, Jörg Kreuter, Martin Michaelis, Jindrich Cinatl
  • Publication number: 20040137174
    Abstract: The invention relates to a gastric juice-resistant device for releasing active substance excipients having delayed intestinal passage from a gastric juice-resistant enclosure, and which serves to increase the active substance concentration in the intestines. The inventive device is characterised in that the active substance excipient containing at least one active substance is provided in the form of a multiparticulate preparation whose individual particles have mucoadhesive properties. The invention also relates to a method for producing said device.
    Type: Application
    Filed: December 30, 2003
    Publication date: July 15, 2004
    Inventors: Despina Solomonidou, Markus Krumme, Bodo Asmussen, Joerg Kreuter
  • Publication number: 20040131692
    Abstract: The present invention relates to nanoparticles for penetrating the blood-brain barrier. The nanoparticles are characterized in that they consist of a hydrophile protein or of a combination of hydrophile proteins, preferably of serum albumin, with particular preference of human origin, to which apolipoprotein E is coupled. The invention further relates to processes for the manufacture of such nanoparticles.
    Type: Application
    Filed: February 11, 2004
    Publication date: July 8, 2004
    Inventors: Joerg Kreuter, Klaus Langer, Carolin Weber, Renad N. Alyautdin
  • Patent number: 6288040
    Abstract: The invention relates to medicament excipient particles which are suitable for tissue-specific application of a medicament, especially to the central nervous system (CNS). The invention particles can be loaded with or be free pf the active substance. At least one detection protein is bonded to the particle surface or alternatively, the particle surface is modified in such a way that a detection protein bonds with it on contact.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: September 11, 2001
    Assignee: DSS Drug Delivery Service Gesellschaft zur Forderung der Foshung In Phamazeutischer Technologi und Biopharmazie mbH
    Inventors: Ranier H. Müller, Martin Lück, Jörg Kreuter